/daily ·07 AUG 2026 ·FRIDAY ·2 MIN READ ·6 STORIES

First mRNA flu vaccine; tau finds a second way to harm

A landmark approval closes a 30-year mRNA loop; a new Alzheimer's study finds tau damages neurons through a second, tangle-independent mechanism.

01 / The Day

FRIDAY 07 AUG 2026, ranked

FDA approves Moderna mFlusiva, the first mRNA influenza vaccine

The FDA approved Moderna's mFlusiva for seasonal influenza, the first mRNA-based flu vaccine to reach market. Phase 3 data showed improved efficacy against H3N2 strains versus egg-based comparators, and the platform allows faster strain reformulation when seasonal predictions change.

Why it mattersmRNA flu vaccines have been a proof-of-concept goal since before COVID. Approval demonstrates the platform can deliver on the original promise beyond coronaviruses — the reformulation speed advantage is its most durable practical edge.

01 statnews.com↗

Tau disrupts DNA repair in neurons, independent of tangle formation

A new study found that hyperphosphorylated tau directly interferes with neuronal DNA double-strand break repair — causing genomic instability as a separate mechanism from the neurofibrillary tangles previously thought to be tau's primary pathology.

Why it mattersTherapies targeting tau aggregation alone may be missing a parallel damage pathway; programs addressing upstream phosphorylation rather than downstream tangles now have stronger mechanistic support.

02 statnews.com↗

SARS-CoV-2 reactivates latent EBV and herpes viruses, study finds

A controlled study found COVID-19 infection reactivates latent Epstein-Barr virus and herpes simplex virus in a meaningful proportion of cases, with reactivation correlating with greater severity and, separately, with long COVID symptom persistence.

Why it mattersViral reactivation as a long COVID mechanism has been hypothesised for years; direct controlled evidence points at latent-herpesvirus antivirals as a candidate intervention class worth studying in trials.

03 statnews.com↗

Replimune RP1 approved for melanoma after two prior FDA rejections

RP1 (vusolimogene oderparepvec), Replimune's oncolytic herpes-virus therapy, received FDA approval for advanced melanoma on its third application, backed by confirmatory Phase 3 data showing durable responses in checkpoint-inhibitor-refractory patients.

Why it mattersAn approval on a third attempt — after two complete response letters — reflects both more complete survival data and a maturing FDA framework for oncolytic virus therapies, a category now with a definitive clinical path.

04 statnews.com↗

Fecal microbiome transplant studied as food allergy treatment in children

A Phase 2 trial evaluated FMT from non-allergic donors in children with peanut allergy; a subset of responders achieved higher peanut tolerance thresholds at 12 months, with gut microbiome shifts consistent with reduced Th2 immune skewing.

Why it mattersFood allergy rates are rising globally; this is among the first controlled human evidence that the gut immune axis is modifiable enough to reduce clinical allergy — small sample, early stage, but a credible signal.

05 statnews.com↗

A participant death in a gene-editing trial triggers FDA hold

A participant in an early-phase gene-editing trial died, prompting the FDA to place a clinical hold on the program pending investigation. The therapy and cause of death remain under review; reporting from STAT News indicates the hold affects a single company's program.

Why it mattersA fatality in gene editing — even if causal connection is unconfirmed — typically prompts broad review of similar programs and raises the bar for consent, monitoring, and dosing protocols across the field.

06 statnews.com↗

Be subscriber #013 the weekly ten, every friday by email · no spam · unsubscribe anytime

Past days

The Daily Archive

/FRI 07 AUGFirst mRNA flu vaccine; tau finds a second way to harm /WED 05 AUGSenolytics, centenarian microbes, and a protein that poisons aging brains /MON 03 AUGProtein, lifespan ceilings, and uneven clocks /FRI 31 JULBlood proteins predict liver disease 16 years early /WED 29 JULWednesday, 29 July — Clocks, guts, heat /MON 27 JULFDA Splits the Peptide Vote, Salk Finds Zombie Cells' Weakness, and GBD Says Healthy Years Aren't Keeping Pace /FRI 24 JULThe Drug That Lost Its Heart /WED 22 JULBlood, bone, and the morbidity gap /FRI 17 JULFriday in Longevity: Clocks, Fat, and Immune Decay /WED 15 JULSenescent terrain /MON 13 JULLecanemab under the skin /FRI 10 JULLongevity | Jul 10 2026: Gut, Senescence, Epigenetics /WED 08 JULDrugs remapped to aging hallmarks, ovarian aging reversed, and a 50% molecular gap /MON 06 JULCentenarian chemistry, sleeping circuits, and reprogrammed eyes /FRI 03 JULOvaries, progenitors, and oxygen /WED 01 JULTelomere signals, proteomic clocks, and faster biological aging /MON 29 JUNMonday, June 29 — Longevity /FRI 26 JUNWhen you sleep matters; what your cells do with miscopied RNA also matters /TUE 23 JUNGenes, Clocks, and GLP-1s /MON 22 JUNMonday: Senescent cells, climbing clocks, and late-life gene therapy /FRI 19 JUNLongevity — June 19, 2026